Literature DB >> 11991262

Sclerosing foam in the treatment of varicose veins and telangiectases: history and analysis of safety and complications.

Alessandro Frullini1, Attilio Cavezzi.   

Abstract

OBJECTIVE: To review the use of sclerosing foam in the treatment of varicose veins, to describe the different techniques of foam preparation, and to report the complications of our 3-year experience with this treatment.
METHOD: From November 1997 to the end of October 2000, 453 patients were treated with a sclerosing foam for large, medium, and minor varicosities with sodium tetradecylsulfate (STS) or polidocanol (POL). A first group of 257 patients (90 for minor varicosities and 167 for medium to large veins) received a sclerosing foam according to the Monfreux technique. From December 1999 to October 2000, 196 patients were treated with a sclerosing foam prepared according to Tessari's method (36 for minor size veins or teleangectasias and 170 for medium-large veins). Every patient was studied with (color-flow) duplex scanning before and after the treatment and large vein injections were administered under duplex guide.
RESULTS: The immediate success rate was 88.1% in the first group for the medium-large veins. In the same districts we registered an early success rate in 93.3% for the patients treated with the Tessari's method. The complication rate (mostly minor complications) was 8.5% in the first group and 7.1% in the second group.
CONCLUSION: The use of sclerosing foam may become an established therapy in the treatment of varicose veins with a high success rate, low cost, and low major complication rate. According to our actual experience and knowledge, the safe amount of foam should not exceed the 3-ml limit, but further advancements could come from standardization of the foam preparation technique.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11991262     DOI: 10.1046/j.1524-4725.2002.01182.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  21 in total

1.  [Surgical therapy of venous leg ulcers].

Authors:  T M Proebstle
Journal:  Hautarzt       Date:  2003-03-11       Impact factor: 0.751

Review 2.  [Sclerotherapy for varicosities].

Authors:  F Pannier; E Rabe
Journal:  Hautarzt       Date:  2006-01       Impact factor: 0.751

Review 3.  The treatment of varicose veins.

Authors:  S Subramonia; T A Lees
Journal:  Ann R Coll Surg Engl       Date:  2007-03       Impact factor: 1.891

4.  Injection sclerotherapy.

Authors:  Robert L Worthington-Kirsch
Journal:  Semin Intervent Radiol       Date:  2005-09       Impact factor: 1.513

Review 5.  Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.

Authors:  Arda Kucukguven; Raouf A Khalil
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

6.  A novel biomimetic analysis system for quantitative characterisation of sclerosing foams used for the treatment of varicose veins.

Authors:  Dario Carugo; Dyan N Ankrett; Vincent O'Byrne; Sean Willis; David D I Wright; Andrew L Lewis; Martyn Hill; Xunli Zhang
Journal:  J Mater Sci Mater Med       Date:  2013-03-20       Impact factor: 3.896

7.  Venous ulcers: new options in treatment: minimally invasive vein surgery.

Authors:  Honesto Poblete; Steven Elias
Journal:  J Am Col Certif Wound Spec       Date:  2009-05-01

8.  Intra-arterial air thrombogenesis after cerebral air embolism complicating lower extremity sclerotherapy.

Authors:  T M Leslie-Mazwi; Laura L Avery; John R Sims
Journal:  Neurocrit Care       Date:  2009-03-17       Impact factor: 3.210

9.  Intra-arterial air thrombogenesis after cerebral air embolism complicating lower extremity sclerotherapy.

Authors:  T M Leslie-Mazwi; Laura L Avery; John R Sims
Journal:  Neurocrit Care       Date:  2009-03-11       Impact factor: 3.210

10.  Treatment of varicose veins: the present and the future--a questionnaire survey.

Authors:  R J Winterborn; C R R Corbett
Journal:  Ann R Coll Surg Engl       Date:  2008-08-12       Impact factor: 1.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.